Table 1.

Clinical characteristics of the 86 patients analyzed by RQ-PCR


Characteristic

Data
Age, y   51  
Median range, y   28-66  
Older than 60 y, no. (%)   13 (15)  
Male, no. (%)   55 (64)  
Disease stage at diagnosis, no. (%)  
   I   1 (1)  
   II   5 (6)  
   III   24 (28)  
   IV   56 (65)  
BM involvement, no. (%)   55 (64)  
Extranodal sites other than BM, no. (%)  
   1   17 (20)  
   2 or more   3 (3)  
B symptoms, no. (%)   8 (9)  
Bulky disease, no. (%)*  15 (17)  
Serum LDH level, no. (%)  
   Normal   73 (85)  
   Elevated   10 (12)  
International prognostic index, no. (%)  
   0-1   56 (65)  
   2 or higher   28 (33)  
   Unknown   2 (2)  
Response to CHOP chemotherapy, no. (%)  
   Complete   51 (59)  
   Partial   28 (32)  
   No response   7 (8)  
Rituximab treatment, no. (%)  
   Yes   49 (57)  
   No
 
37 (43)
 

Characteristic

Data
Age, y   51  
Median range, y   28-66  
Older than 60 y, no. (%)   13 (15)  
Male, no. (%)   55 (64)  
Disease stage at diagnosis, no. (%)  
   I   1 (1)  
   II   5 (6)  
   III   24 (28)  
   IV   56 (65)  
BM involvement, no. (%)   55 (64)  
Extranodal sites other than BM, no. (%)  
   1   17 (20)  
   2 or more   3 (3)  
B symptoms, no. (%)   8 (9)  
Bulky disease, no. (%)*  15 (17)  
Serum LDH level, no. (%)  
   Normal   73 (85)  
   Elevated   10 (12)  
International prognostic index, no. (%)  
   0-1   56 (65)  
   2 or higher   28 (33)  
   Unknown   2 (2)  
Response to CHOP chemotherapy, no. (%)  
   Complete   51 (59)  
   Partial   28 (32)  
   No response   7 (8)  
Rituximab treatment, no. (%)  
   Yes   49 (57)  
   No
 
37 (43)
 
*

Bulky disease was defined as more than 10 cm

Patients not eligible for rituximab were those who had a molecular CR (n = 30) and those who had no response to CHOP (n = 7)

or Create an Account

Close Modal
Close Modal